Yıldırım Malik Ejder, Karakuş Savas, Kurtulgan Hande Küçük, Kılıçgün Hasan, Erşan Serpil, Bakır Sevtap
Faculty of Medicine, Department of Medical Genetics, Cumhuriyet University, 58140, Sivas, Turkey.
Faculty of Medicine, Department of Obstetrics and Gynecology, Cumhuriyet University, 58140, Sivas, Turkey.
Biochem Genet. 2017 Aug;55(4):314-321. doi: 10.1007/s10528-017-9796-7. Epub 2017 Mar 16.
Plasminogen activator inhibitor type 1 (PAI-1) is a serine protease inhibitor (Serpine 1), and it inhibits both tissue plasminogen activator and urokinase plasminogen activator which are important in fibrinolysis. We aimed to find whether there is a possible association between PAI-1 level, PAI-1 4G/5G polymorphism, and endometrial cancer. PAI-1 levels in peripheral blood were determined in 82 patients with endometrial carcinoma and 76 female healthy controls using an enzyme-linked immunoassay (ELISA). Then, the genomic DNA was extracted and screened by reverse hybridization procedure (Strip assay) to detect PAI 1 4G/5G polymorphism. The levels of PAI-1 in the patients were higher statistically in comparison to controls (P < 0.001). The distribution of PAI-1 4G/5G polymorphism was quite different between patients and controls (P = 0.008), and 4G allelic frequency was significantly higher in the patients of endometrial cancer than in controls (P = 0.026). We found significant difference between Grade 1 and Grade 2+3 patients in terms of the PAI-1 levels (P = 0.047). There was no association between PAI-1 4G/5G polymorphism and the grades of endometrial cancer (P = 0.993). Our data suggest that the level of PAI-1 and PAI-1 4G/5G gene polymorphism are effective in the formation of endometrial cancer. PAI-1 levels are also associated with the grades of endometrial cancer.
纤溶酶原激活物抑制剂1（PAI-1）是一种丝氨酸蛋白酶抑制剂（丝氨酸蛋白酶抑制剂1），它能抑制组织纤溶酶原激活物和尿激酶型纤溶酶原激活物，这两种物质在纤维蛋白溶解过程中起着重要作用。我们旨在探究PAI-1水平、PAI-1 4G/5G多态性与子宫内膜癌之间是否存在可能的关联。采用酶联免疫吸附测定法（ELISA）测定了82例子宫内膜癌患者和76例健康女性对照者外周血中的PAI-1水平。然后，提取基因组DNA并通过反向杂交程序（条带分析法）进行筛查，以检测PAI 1 4G/5G多态性。与对照组相比，患者体内PAI-1水平在统计学上更高（P < 0.001）。PAI-1 4G/5G多态性在患者和对照组之间的分布差异很大（P = 0.008），子宫内膜癌患者的4G等位基因频率显著高于对照组（P = 0.026）。我们发现1级和2 + 3级患者在PAI-1水平方面存在显著差异（P = 0.047）。PAI-1 4G/5G多态性与子宫内膜癌的分级之间没有关联（P = 0.993）。我们的数据表明，PAI-1水平和PAI-1 4G/5G基因多态性在子宫内膜癌的形成中起作用。PAI-1水平也与子宫内膜癌的分级有关。
